AxoGen (NASDAQ:AXGN) Director William Mr. Burke Sells 11,431 Shares of Stock

AxoGen, Inc. (NASDAQ:AXGN) Director William Mr. Burke sold 11,431 shares of AxoGen stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $24.05, for a total transaction of $274,915.55. Following the completion of the transaction, the director owned 100 shares of the company’s stock, valued at $2,405. The trade was a 99.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

AxoGen Stock Performance

Shares of AXGN stock opened at $23.57 on Friday. The firm’s 50 day moving average is $17.89 and its 200 day moving average is $14.50. The stock has a market capitalization of $1.09 billion, a P/E ratio of -471.40 and a beta of 1.09. AxoGen, Inc. has a 12 month low of $9.22 and a 12 month high of $24.25. The company has a current ratio of 4.14, a quick ratio of 2.67 and a debt-to-equity ratio of 0.59.

AxoGen (NASDAQ:AXGN) last issued its earnings results on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. AxoGen had a negative net margin of 0.98% and a negative return on equity of 1.96%. The business had revenue of $60.08 million for the quarter, compared to analysts’ expectations of $56.90 million. AxoGen has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that AxoGen, Inc. will post -0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. HC Wainwright raised their target price on AxoGen from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Citigroup restated a “market outperform” rating on shares of AxoGen in a research report on Thursday, October 30th. Raymond James Financial boosted their price objective on shares of AxoGen from $20.00 to $27.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Wall Street Zen raised shares of AxoGen from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Canaccord Genuity Group raised their price target on shares of AxoGen from $24.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.86.

Hedge Funds Weigh In On AxoGen

Institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of AxoGen by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,185 shares of the medical equipment provider’s stock valued at $466,000 after buying an additional 1,057 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in AxoGen by 7.1% in the second quarter. The Manufacturers Life Insurance Company now owns 16,194 shares of the medical equipment provider’s stock valued at $176,000 after acquiring an additional 1,079 shares during the last quarter. Arizona State Retirement System raised its position in AxoGen by 10.0% during the third quarter. Arizona State Retirement System now owns 12,801 shares of the medical equipment provider’s stock valued at $228,000 after purchasing an additional 1,164 shares in the last quarter. Primoris Wealth Advisors LLC lifted its stake in AxoGen by 9.0% during the second quarter. Primoris Wealth Advisors LLC now owns 15,700 shares of the medical equipment provider’s stock worth $170,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Hsbc Holdings PLC boosted its holdings in shares of AxoGen by 6.5% in the 1st quarter. Hsbc Holdings PLC now owns 24,174 shares of the medical equipment provider’s stock worth $432,000 after purchasing an additional 1,468 shares in the last quarter. Institutional investors own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.